Latest news with #Chartreux
GMA Network
a day ago
- Entertainment
- GMA Network
Will Ashley reunites with pet cat Jerry
Will Ashley surely missed his pet cat Jerry! On Instagram Stories, the 'Pinoy Big Brother: Celebrity Collab Edition' Big Four finalist shared a selfie together with his two-year-old Chartreux cat whom he named after the character he played in "Unbreak My Heart." 'Missed my baby,' he simply wrote. Will is a certified fur dad, previously sharing some photos of his beloved cat. He recently attended the fundraising gig "Meowsika at Barkadahan' with fellow housemate Bianca De Vera. The event was organized by their fans in support of Pawssion Project, a non-profit organization committed to rescuing, rehabilitating, and rehoming abused and neglected animals. Will ended his "PBB" journey as the second big placer alongside his duo Ralph De Leon. As he returned to the outside world, the Sparkle star is gearing up for a movie comeback as he stars as Arvin in 'Bar Boys: After School.' —Jade Veronique Yap/CDC, GMA Integrated News
India.com
6 days ago
- Lifestyle
- India.com
PAWsitively Mesmerising: These 7 Cat Breeds Have The Most Captivating Eyes
photoDetails english 2928999 Updated:Jul 09, 2025, 11:40 AM IST 1 / 9 Cats are captivating creatures, but some breeds take allure to a whole new level—especially with their stunning eyes. From deep sapphires to emerald greens, these cat breeds have eyes so mesmerizing, they'll stop you in your tracks. Whether you're a feline enthusiast or just love pretty pets, here are 7 cat breeds known for their eye-catching, heart-melting gazes. Siamese – The Sapphire-Eyed Stunner 2 / 9 Siamese cats are famous for their almond-shaped, vivid blue eyes that stand out against their sleek, short coats. These eyes aren't just beautiful—they're also incredibly expressive, reflecting the Siamese's talkative and affectionate personality. Their eye color is a signature trait that makes them one of the most elegant and striking cat breeds. Turkish Angora – Ice-Blue or Odd-Eyed Elegance 3 / 9 The Turkish Angora often boasts bright blue or green eyes, and sometimes even has odd eyes (one blue, one amber). Paired with their silky white fur and graceful build, their unique eyes make them look almost ethereal. Their beauty is matched by their playful, intelligent nature, making them charming companions. Russian Blue – Emerald-Eyed Mystery 4 / 9 With their plush silvery-blue coats and striking emerald-green eyes, Russian Blues radiate quiet elegance. Their vivid eyes develop gradually, turning from yellow to green as they mature. This reserved and loyal breed carries an air of mystery, making their glowing green eyes all the more captivating. Ragdoll – Deep Blue, Dreamy Gaze 5 / 9 Ragdolls are large, affectionate cats known for their plush coats and deep blue eyes. Their eye color is a trademark of the breed and adds to their soft, doll-like appearance. Ragdolls are famously relaxed and cuddly, and their gaze often mirrors their gentle, trusting temperament. Bengal – Wild Look with Gold or Green Intensity 6 / 9 Bengal cats combine exotic, leopard-like patterns with wild, piercing eyes in shades of gold, green, or even aqua. Their eyes are often round and intense, reflecting their high energy and curiosity. Their jungle-cat appearance and stunning eyes give them an unforgettable presence. Chartreux – Copper-Eyed Charm 7 / 9 The Chartreux is a rare French breed with a luxurious blue-gray coat and brilliant copper or gold eyes. The contrast between their smoky fur and fiery eyes gives them a unique, mysterious charm. These cats are known for being quiet, observant, and incredibly loyal—true hidden gems in the cat world. Scottish Fold – Round Eyes Full of Emotion 8 / 9 Scottish Folds, known for their distinctive folded ears, also have large, round eyes that seem to sparkle with emotion. Their eyes come in various colors depending on coat shade—often gold, green, or copper—and give them a sweet, almost cartoonish appearance that's impossible to resist. 9 / 9 Each of these breeds brings a special kind of beauty to the feline world, with eyes that captivate and hearts that steal yours. Whether you're drawn to vivid blues, glowing greens, or golden hues, these cats prove that the eyes truly are the windows to the soul—even in the animal kingdom.
Associated Press
12-06-2025
- Health
- Associated Press
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. 'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.' FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. 'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.' Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal
Yahoo
12-06-2025
- Health
- Yahoo
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. "Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease," said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. "It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care." FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. "Veterinarians have long-needed options beyond palliative care when it comes to feline HCM," said Dr. Joshua Stern, DVM, PhD, DACVIM. "With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception." Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
